Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Probenecid

FDA-approved product (tablet, oral), marketed as Benemid, Probalan, Probenecid.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Probenecid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Gout

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Preparations increasing uric acid excretion
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli18.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae6.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Probenecid in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Probenecid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks

    NCT00000670

    Registered record
    Registry ID
    NCT00000670
    Conditions
    HIV Infections
    Interventions
    Probenecid; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1989-07
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionProbenecid; Zidovudine
    PhaseNot applicable
    Registry statusCompleted

  • Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine

    NCT00000706

    Registered record
    Registry ID
    NCT00000706
    Conditions
    HIV Infections
    Interventions
    Quinine sulfate; Probenecid; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1988-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionQuinine sulfate; Probenecid; Zidovudine
    PhaseNot applicable
    Registry statusCompleted

  • A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease

    NCT00000881

    Registered record
    Registry ID
    NCT00000881
    Conditions
    Cytomegalovirus Infections; Cytomegalovirus Retinitis; HIV Infections
    Interventions
    Cidofovir; Probenecid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections; Cytomegalovirus Retinitis; HIV Infections
    InterventionCidofovir; Probenecid
    PhasePhase 1
    Registry statusWithdrawn

  • A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients

    NCT00000945

    Registered record
    Registry ID
    NCT00000945
    Conditions
    HIV Infections; Leukoencephalopathy, Progressive Multifocal
    Interventions
    Cidofovir; Probenecid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2001-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Leukoencephalopathy, Progressive Multifocal
    InterventionCidofovir; Probenecid
    PhaseNot applicable
    Registry statusCompleted

  • The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

    NCT00002437

    Registered record
    Registry ID
    NCT00002437
    Conditions
    Cytomegalovirus Retinitis; HIV Infections
    Interventions
    Cidofovir; Probenecid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Retinitis; HIV Infections
    InterventionCidofovir; Probenecid
    PhasePhase 2
    Registry statusCompleted